Table 2.
Properties of CRISPR based COVID-19 detection assays.
| platform name | Sample size | Cas protein | Time(min) | lod | Sensitivity (%) |
Specificity (%) |
Visualization | Target genes | Amplification system | Amplification temperature | Qualitative/ Quantitative |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AIOD-CRISPR | 28 | Cas12a | 20 | 5 | N/A | N/A | Naked eye | N | RT-RPA | 37 | Qualitative |
| SHERLOCK | 534 | Cas13a | 35 | 42 | flu96/ 88 lateral | 100 | Fluorescent /lateral flow | S | RRT-RPA | 37 | Quantitative |
| SARS-CoV-2 DETECTR | 11 | Cas12a | 30 | 10 | 90 | 100 | Lateral flow | E,N | RT- LAMP | 62 | Qualitative |
| CRISPR/Cas12a-NER | 31 | Cas12a | 45 | 10 | N/A | N/A | Fluorescent | E | RT-RAA | 39 | Qualitative |
| CRISPR based DETECTR | 378 | Cas12a | 30 | 50 | 95 | 100 | Lateral flow | N | RT-LAMP | 62 | Qualitative |
| STOPCovid.v1 | 17 | Cas12b | 50 | 100 | N/A | N/A | Lateral flow | N | RT- LAMP | 60 | Quantitative |
| STOPCovid.v2 | 402 | Cas12b | 15−45 | 40.3 | 93.1 | 98.5 | Fluorescent /lateral flow | N | LAMP | N/A | N/A |
| CONAN | 25 | Cas3 | 40 | 1 | N/A | N/A | Lateral flow | N | RT-RPA | 37 | Qualitative |
| CREST | N/A | Cas13a | 120 | 10 | N/A | N/A | Fluorescent | N | PCR | N/A | Quantitative |